Image

    Fulvestrant: A New Treatment Option for Advanced Breast Cancer - Tolerability Versus Existing Agents

    October 2005 in “ Annals of Oncology ”
    Ignace Vergote, P Abram
    Studysummary This review found that fulvestrant is well tolerated in postmenopausal women with hormone receptor-positive advanced breast cancer, showing lower incidence of joint disorders than non-steroidal aromatase inhibitors.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on annalsofoncology.org →
    Discuss this study in the Community →

    Related research 1

    1. Fulvestrant: A New Treatment Option for Advanced Breast Cancer - Tolerability Versus Existing Agents Annals of Oncology · 2005